| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
Venous thromboembolism has attracted attention in recent years as economy class syndrome. In a congenital mutation of the blood coagulation factor control it has been known to increase the risk even in heterozygotes. We found an abnormal prothrombin to resist the control of the coagulation control factor antithrombin by one amino acid mutations, proposed an anti-thrombin resistance as a new disease concept. Thrombin loses the clotting ability to bind to receptor-thrombomodulin of vascular endothelial cell surface, so to exert an anti-clotting ability. We have developed a more of method for measuring changes in coagulation control ability of thrombomodulin by prothrombin mutation. In addition, we are focusing on the blood coagulation factor Xa inhibited by antithrombin.
We found abnormal FXs showing the antithrombin resistance. We have developed a method for analysis of FXa antithrombin resistance.
|
